BTAI
Price
$2.58
Change
+$0.11 (+4.45%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
48.53M
CRMD
Price
$11.21
Change
-$0.23 (-2.01%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
853.98M
43 days until earnings call
Interact to see
Advertisement

BTAI vs CRMD

Header iconBTAI vs CRMD Comparison
Open Charts BTAI vs CRMDBanner chart's image
BioXcel Therapeutics
Price$2.58
Change+$0.11 (+4.45%)
Volume$3.59K
Capitalization48.53M
CorMedix
Price$11.21
Change-$0.23 (-2.01%)
Volume$21.31K
Capitalization853.98M
BTAI vs CRMD Comparison Chart in %
Loading...
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BTAI vs. CRMD commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BTAI is a StrongBuy and CRMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (BTAI: $2.47 vs. CRMD: $11.44)
Brand notoriety: BTAI and CRMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BTAI: 15% vs. CRMD: 84%
Market capitalization -- BTAI: $48.53M vs. CRMD: $853.98M
BTAI [@Biotechnology] is valued at $48.53M. CRMD’s [@Biotechnology] market capitalization is $853.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BTAI’s FA Score shows that 0 FA rating(s) are green whileCRMD’s FA Score has 1 green FA rating(s).

  • BTAI’s FA Score: 0 green, 5 red.
  • CRMD’s FA Score: 1 green, 4 red.
According to our system of comparison, CRMD is a better buy in the long-term than BTAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BTAI’s TA Score shows that 4 TA indicator(s) are bullish while CRMD’s TA Score has 4 bullish TA indicator(s).

  • BTAI’s TA Score: 4 bullish, 6 bearish.
  • CRMD’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CRMD is a better buy in the short-term than BTAI.

Price Growth

BTAI (@Biotechnology) experienced а -17.39% price change this week, while CRMD (@Biotechnology) price change was -1.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

CRMD is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRMD($854M) has a higher market cap than BTAI($48.5M). CRMD YTD gains are higher at: 41.235 vs. BTAI (-58.712). CRMD has higher annual earnings (EBITDA): 52.3M vs. BTAI (-34.61M). CRMD has more cash in the bank: 191M vs. BTAI (17.4M). CRMD has less debt than BTAI: CRMD (435K) vs BTAI (109M). CRMD has higher revenues than BTAI: CRMD (121M) vs BTAI (868K).
BTAICRMDBTAI / CRMD
Capitalization48.5M854M6%
EBITDA-34.61M52.3M-66%
Gain YTD-58.71241.235-142%
P/E RatioN/A14.67-
Revenue868K121M1%
Total Cash17.4M191M9%
Total Debt109M435K25,057%
FUNDAMENTALS RATINGS
BTAI vs CRMD: Fundamental Ratings
BTAI
CRMD
OUTLOOK RATING
1..100
5158
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
10069
SMR RATING
1..100
10025
PRICE GROWTH RATING
1..100
6355
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRMD's Valuation (53) in the Medical Specialties industry is in the same range as BTAI (78) in the Biotechnology industry. This means that CRMD’s stock grew similarly to BTAI’s over the last 12 months.

CRMD's Profit vs Risk Rating (69) in the Medical Specialties industry is in the same range as BTAI (100) in the Biotechnology industry. This means that CRMD’s stock grew similarly to BTAI’s over the last 12 months.

CRMD's SMR Rating (25) in the Medical Specialties industry is significantly better than the same rating for BTAI (100) in the Biotechnology industry. This means that CRMD’s stock grew significantly faster than BTAI’s over the last 12 months.

CRMD's Price Growth Rating (55) in the Medical Specialties industry is in the same range as BTAI (63) in the Biotechnology industry. This means that CRMD’s stock grew similarly to BTAI’s over the last 12 months.

CRMD's P/E Growth Rating (98) in the Medical Specialties industry is in the same range as BTAI (100) in the Biotechnology industry. This means that CRMD’s stock grew similarly to BTAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BTAICRMD
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 17 days ago
81%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSHEX29.121.41
+5.09%
Kinetics Spin-Off and Corp Rest No Load
PAREX12.030.08
+0.67%
T. Rowe Price Real Estate Advisor
BIIEX27.250.15
+0.55%
Brandes International Equity I
MSFRX20.120.04
+0.20%
MFS Total Return A
FVRMX26.190.02
+0.08%
Franklin Mutual Small-Mid Cap Val Adv

BTAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BTAI has been loosely correlated with TENX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if BTAI jumps, then TENX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BTAI
1D Price
Change %
BTAI100%
-11.15%
TENX - BTAI
37%
Loosely correlated
+1.56%
SYBX - BTAI
37%
Loosely correlated
+0.99%
SBHMY - BTAI
32%
Poorly correlated
N/A
CRMD - BTAI
29%
Poorly correlated
+1.51%
CASI - BTAI
29%
Poorly correlated
-8.98%
More

CRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with MURA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then MURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRMD
1D Price
Change %
CRMD100%
+1.51%
MURA - CRMD
37%
Loosely correlated
+0.97%
HOTH - CRMD
30%
Poorly correlated
+6.70%
FULC - CRMD
30%
Poorly correlated
-1.34%
BTAI - CRMD
30%
Poorly correlated
-11.15%
HRMY - CRMD
29%
Poorly correlated
-1.08%
More